Natalizumab (Tysabri) Pharmacokinetic ELISA

Natalizumab (Tysabri) Pharmacokinetic ELISA

• Description: Natalizumab (Tysabri®) is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin used in the treatment of multiple sclerosis and Crohn's disease. Tysabri® and was previously named Antegren®. Natalizumab is administered by intravenous infusion every 28 days and reduces the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood– brain barrier.
• CAS Number: 7732-18-5
• Gene ID: 1956
• Reaction Volume: 15 µL
• Target Antigen: Natalizumab (Tysabri)
• Detection Method: Direct sandwich ELISA
• Assay Principle: Quantification of Natalizumab in biological matrices
• Assay Protocol: This assay employs the sandwich enzyme immunoassay technique. Capture antibody is coated onto a 96 well microplate. Calibrator and test samples are pipetted into the appropriate wells. Natalizumab present in biological matrices is bound by the immobilized anti-Natalizumab antibody. After washing away any unbound substances, enzyme linked anti-Natalizumab antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Natalizumab present in test samples. The color development is stopped and the intensity of the color is measured.
• Assay Performance Time: 2.5 Hours
• Sample Type: Serum Plasma
• Detection Range: 50ng/mL - 1.56ng/mL
• Precision: <10%, <10%
• Sensitivity: Natalizumab
• Limit Of Detection: 1.5 ng/mL
• Components: Coated microtiter plate, 96 wells Calibrator diluent. - 1.8mL Calibrator 12ul 10X wash buffer - 25mL Assay buffer - 50mL 1000X detection reagent - 17ul TMB - 12mL TMB stop solution - 12mL Plate sealers - 3
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C
• Shelf Life: 12 months